Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems Q4 Earnings Call Highlights
04:50am, Sunday, 01'st Mar 2026
Delcath Systems (NASDAQ: DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding treatment-ce
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
03:17pm, Thursday, 26'th Feb 2026
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
08:00am, Thursday, 26'th Feb 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
08:00am, Thursday, 12'th Feb 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it
Micron Solutions (OTCMKTS:MICR) and Delcath Systems (NASDAQ:DCTH) Critical Review
01:44am, Monday, 02'nd Feb 2026
Micron Solutions (OTCMKTS:MICR - Get Free Report) and Delcath Systems (NASDAQ: DCTH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the tw
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08:05am, Tuesday, 27'th Jan 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 21'st Jan 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) PT at $22.40
03:52am, Wednesday, 14'th Jan 2026
Delcath Systems, Inc. (NASDAQ: DCTH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the company, Marketbeat reports.
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
12:22pm, Tuesday, 13'th Jan 2026
Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earl
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
08:05am, Friday, 09'th Jan 2026
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic live
Delcath Systems (NASDAQ:DCTH) vs. AngioDynamics (NASDAQ:ANGO) Head-To-Head Survey
02:14am, Thursday, 11'th Dec 2025
Delcath Systems (NASDAQ: DCTH - Get Free Report) and AngioDynamics (NASDAQ: ANGO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two bu
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic live
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
04:01pm, Thursday, 20'th Nov 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, tod
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic live
